Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

NEW DRUG APPLICATION (NDA) OF RADEMIKIBART WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on April 29, 2026, New Drug Application (NDA) of the innovative drug Rademikibart, jointly developed by the Group and Connect Biopharma Hong Kong Limited (香港康乃德生物醫藥有限公司), resubmitted by the Group, was accepted by the National Medical Products Administration (NMPA) for the treatment of atopic dermatitis in adults and adolescents.

ABOUT RADEMIKIBART

Rademikibart is a fully human monoclonal antibody targeting IL-4R α , a common subunit of IL-4 receptor and IL-13 receptor. By binding with IL-4R α , Rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the Th2 inflammatory pathway, thus achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis and asthma.

The phase 3 clinical studies showed that Rademikibart not only acts rapidly but also demonstrates significant cumulative benefits with continued treatment, showing potential for greater effectiveness compared to similar class of products. At week16, the response rates for EASI-75, EASI-90 and IGA 0/1 in the Rademikibart group reached 74.2%, 43.0% and 47.7% ($p<0.0001$), respectively, indicating clear clinical benefits in early treatment. By Week 52, the response rates for EASI-75, EASI-90 and IGA 0/1 had increased to 96.6%, 85.3% and 87.1%, respectively, demonstrating a significant advantage in deep remission with long-term treatment.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "for patients, for life". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. REN Jinsheng
Chairman and Executive Director

Hong Kong, April 30, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; and Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.